$1.15
(5.32%)
Add to watchlist
Create an alert
Stocks and Shares ISADenali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. It has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). It is also exploring programs in oncology, inflammation, and other diseases.
Company Information
About this company
Key people
Julian C. Baker
Independent Chairman of the Board
Ryan J. Watts
President, Chief Executive Officer, Director
Alexander O. Schuth
Co-Founder, Chief Operating Officer, Head of Corporate Development
Peter Chin
Acting Chief Medical Officer, Head - Development
Steven E. Krognes
Director
Tim van Hauwermeiren
Director
Jennifer E. Cook
Independent Director
Jay T. Flatley
Director
Click to see more
Key facts
- Shares in issue158.59m
- EPICDNLI
- ISINUS24823R1059
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$3.43bn
- Employees503
- ExchangeNASDAQ
- IndexTR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.